Antibody Cocktail Therapy Given to First Covid-19 Patient in Ahmedabad
After the therapy was
approved in India earlier this month, CIMS Hospital became the first private facility in Gujarat’s Ahmedabad to administer an antibody cocktail to a
Covid-19 patient.
The
monoclonal antibody cocktail treatment was launched in India just last week for
treating mild Covid-19 patients. A 38-year-old diabetic male patient with
Covid-19 symptoms were administered the antibody cocktail of Casirivimab and
Imdevimab. CIMS is the first hospital in Ahmedabad to begin this treatment.
According
to Doctors, the cocktail treatment is recommended only in the early stages of
the Covid-19 infection and for high-risk patients. It is the same treatment
that former US President Donald Trump received last year.
The
patient we administered the combination medication today has diabetes and
hence belongs to the high-risk group. The high mortality in young males during
the second wave has been a grave concern for the medical fraternity. This
medication is not recommended for Covid-19 patients who have moderate or severe
disease with hypoxia.
According to the Covid Care Team of CIMS Hospital, the antibody
cocktail therapy can be given to high-risk patients in the early stages of
Covid-19 infection, displaying very mild or mild symptoms, and not having any
oxygen requirement.

Comments
Post a Comment